JP Morgan Chase
NKTR icon

JP Morgan Chase’s Nektar Therapeutics NKTR Stock Holding History

JP Morgan Chase’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-847
Closed -$68K – 6740
2022
Q1 		$68K Buy
847
+80
+10% +$11.8K ﹤0.01% 5675
2021
Q4 		$155K Buy
+767
New +$166K ﹤0.01% 5486
2021
Q2 		– Sell
-3,307
Closed -$992K – 6523
2021
Q1 		$992K Buy
+3,307
New +$1.03M ﹤0.01% 4237
2020
Q1 		– Sell
-6,973
Closed -$2.26M – 5585
2019
Q4 		$2.26M Sell
6,973
-360
-5% -$104K ﹤0.01% 3305
2019
Q3 		$2M Buy
7,333
+3,333
+83% +$1.22M ﹤0.01% 3417
2019
Q2 		$2.08M Sell
4,000
-2,000
-33% -$1M ﹤0.01% 3356
2019
Q1 		$3.02M Buy
6,000
+2,333
+64% +$1.38M ﹤0.01% 3027
2018
Q4 		$1.81M Buy
3,667
+2,667
+267% +$1.61M ﹤0.01% 3349
2018
Q3 		$914K Sell
1,000
-1,000
-50% -$854K ﹤0.01% 3978
2018
Q2 		$1.47M Buy
+2,000
New +$2.31M ﹤0.01% 3615
2018
Q1 		– Sell
-1,800
Closed -$1.61M – 5544
2017
Q4 		$1.61M Buy
+1,800
New +$1.06M ﹤0.01% 3439
2017
Q3 		– Sell
-6,947
Closed -$2.04M – 5096
2017
Q2 		$2.04M Hold
6,947
– – ﹤0.01% 3036
2017
Q1 		$2.45M Buy
+6,947
New +$1.56M ﹤0.01% 2923

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase's NKTR Position: Q1 2026 in Review

JP Morgan Chase increased its Nektar Therapeutics (NKTR) stake by 59% in Q1 2026, buying an estimated $5.08M and bringing the position to 240,102 shares worth $15.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2289.

JP Morgan Chase first reported a position in NKTR in Q2 2013 and has held it in 52 quarters since. The position peaked at $135M in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • JP Morgan Chase held 240,102 shares of Nektar Therapeutics worth $15.7M as of Q1 2026.
  • JP Morgan Chase bought 89,298 Nektar Therapeutics shares in Q1 2026, an estimated $5.08M.
  • Nektar Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2289 holding.
  • JP Morgan Chase first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • JP Morgan Chase's Nektar Therapeutics position peaked at $135M in Q1 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.